Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1649 1675
This examiner grants 33% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18455205 | MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY | Non-Final OA | Iowa State University Research Foundation, Inc. |
| 17304444 | MICROENCAPSULATED AND CHROMOSOME INTEGRATED COMPOSITIONS FOR L-DOPA MICROBIOME THERAPY | Non-Final OA | Iowa State University Research Foundation, Inc. |
| 17784145 | COMPOSITIONS AND METHODS FOR TREATING NEUROMUSCULAR DISORDERS | Non-Final OA | The Regents of the University of California |
| 18011965 | PREVENTION OF AXONAL DAMAGE USING ANTIBODY BINDING TO AMYLOID BETA 1-42 | Non-Final OA | Eli Lilly and Company |
| 17790340 | LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES | Final Rejection | Ohio State Innovation Foundation |
| 17762543 | VACCINE THERAPY FOR RAN PROTEIN DISEASES | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18278068 | DYNAMIC BIOACTIVE SCAFFOLDS AND THERAPEUTIC USES THEREOF AFTER CNS INJURY | Final Rejection | Northwestern University |
| 17924461 | PEPTIDE USED TO PREVENT OR TREAT SYNUCLEINOPATHY | Non-Final OA | TOHOKU UNIVERSITY |
| 18560791 | CHIMERIC ANTIGEN RECEPTOR TO TARGET HLA-G-POSITIVE CANCERS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17753635 | Management of conditions other than multiple sclerosis in ofatumumab-treated patients | Final Rejection | Novartis AG |
| 17769705 | EXTRACELLULAR VESICLE-BASED AGENTS AND METHODS FOR THE TREATMENT OF NEUROPATHIC DISORDERS | Non-Final OA | University of Washington |
| 18110960 | METHOD AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS | Non-Final OA | RAMOT AT TEL AVIV UNIVERSITY LTD. |
| 17801776 | METHODS OF USE OF ANTI-TREM2 ANTIBODIES | Non-Final OA | Washington University |
| 17268664 | TREATING SPINAL CORD INJURY (SCI) AND BRAIN INJURY USING GSX1 | Non-Final OA | Rutgers, The State University of New Jersey |
| 16876353 | EFFICIENT, SCALABLE PRODUCTION OF HUMAN RETINAL PROGENITORS IN VITRO | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18611374 | APOE ANTIBODIES, FUSION PROTEINS AND USES THEREOF | Non-Final OA | Massachusetts Eye and Ear Infirmary |
| 16608719 | BI- OR MULTI-DIFFERENTIATED ORGANOID | Non-Final OA | IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy